.png)
.png)
Послать статью по эл. почте 
От ХандиХалера к Респимату: пути доставки тиотропия
https://doi.org/10.18093/0869-0189-2013-0-4-131-134
Аннотация
От ХандиХалера к Респимату: пути доставки тиотропия.
Об авторах
А. А. ВизельРоссия
д. м. н., профессор, зав. кафедрой фтизиопульмонологии
420012, Республика Татарстан, Казань, ул. Бутлерова, 49. Тел.: (987) 296-25-99.
И. Ю. Визель
Россия
к. м. н., профессор РАЕ, ассистент кафедры фтизиопульмонологии
420012, Республика Татарстан, Казань, ул. Бутлерова, 49. Тел.: (843) 279-80-03.
Список литературы
1. Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med 2009; 180 (10): 948–955.
2. Ichinose M., Fujimoto T., Fukuchi Y. Tiotropium 5 mcg via Respimat and 18 mg via HandiHaler1; efficacy and safety in Japanese COPD patients. Respir. Med. 2010; 104 (2): 228–236.
3. Bateman E.D., Singh D., Smith D. et al. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 197–208.
4. Ram F.S., Carvallho C.R., White J. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 129–139.
5. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J.A.M.A. 2008; 300 (12): 1439–1450.
6. Ram F.S. Spiriva (Respimat) increases mortality by 52 % in patients with COPD: time to take action. N. Z. Med. J. 2011; 124 (1337): 117–118.
7. Beasley R. Tiotropium Respimat increases the risk of mortality: pro. Eur. Respir. J. 2013; 42 (3): 584–589.
8. Stewart H.J. The effect of increased heart rate due to the injection of atropine on the oxygen saturation of the arterial and venous blood of patients with heart disease. J. Clin. Invest. 1926; 3 (2): 241–251.
9. Peters N.L. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch. Intern. Med. 1989; 149 (11): 2414–2420.
10. Bateman E.D. Tiotropium Respimat increases the risk of mortality: con. Eur. Respir. J. 2013; 42: 590–593.
11. Beier J., Kirsten A.M., Mruz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: Results from a 6-week, randomized, controlled phase iiib study. COPD 2013; 10 (4): 511–522.
12. D'Urzo A. Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD. Ther. Clin. Risk. Manag. 2013; 9: 341–353.
13. Singh S., Loke Y.K., Enright P.L. et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and metaanalysis of randomized controlled trials. Br. Med. J. 2011; 342: d3215.
14. US National Institutes of Health. ClinicalTrials.gov. Tiotropium Respimat pharmacokinetic study in COPD. 2010. www.clinicaltrials.gov/ct2/show/results/NCT01222533
15. Khorfan F.M., Smith P., Watt S., Barber K.R. Effects of nebulized bronchodilator therapy on heart rate and arrhythmias in critically ill adult patients. Chest. 2011; 140 (6): 1466–1472.
16. Abrahams R., Moroni3Zentgraf P., Ramsdell J. et al. Safety and efficacy of the once-daily anticholinergic BEA2180 compared to tiotropium in patients with COPD. Respir. Med. 2013; 107 (6): 854–862.
17. Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013 Aug 30 [Epub ahead of print].
Дополнительные файлы
Для цитирования: Визель А.А., Визель И.Ю. От ХандиХалера к Респимату: пути доставки тиотропия. Пульмонология. 2013;(4):131-134. https://doi.org/10.18093/0869-0189-2013-0-4-131-134
For citation: Vizel A.A., Vizel I.Y. From Handihaler to Respimat: tiotropium delivery systems. Russian Pulmonology. 2013;(4):131-134. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-4-131-134
Обратные ссылки
- Обратные ссылки не определены.